Blunschi Fabienne, Muthmann Sofie, Bauer Natali, Hazuchova Katarina
Clinic for Small Animals (Internal Medicine, Clinical Pathology and Clinical Pathophysiology), Justus-Liebig-University,35392 Giessen, Germany.
Vet Sci. 2025 Jun 11;12(6):572. doi: 10.3390/vetsci12060572.
A previous cross-sectional study found impaired health-related quality of life (HRQoL) in hyperthyroid cats, but the longitudinal impact of treatment-especially differences between radioiodine (RAIT) and antithyroid drug (ATD) approaches-remains unclear. This study aimed to evaluate changes in HRQoL in recently diagnosed (<6 months) hyperthyroid cats that underwent RAIT or received ATD. HRQoL was assessed using the validated HyperthyroidismQoL-cat questionnaire at baseline and after 1, 3, and 6 months, alongside thyroid status (eu-/hypo-/hyperthyroid) evaluation. Mixed-effects model analysed the influence of treatment type, timepoint, and thyroid status on log(HRQoL). HRQoL differences between groups at baseline and comparison to a non-hyperthyroid control group (n = 322) from a previous study at month 6 were examined using Mann-Whitney U tests. Data are presented as median (range), with significance set at < 0.05. Thirty-eight client-owned hyperthyroid cats (15 ATD, 23 RAIT) were included. HRQoL scores at baseline did not differ between groups (RAIT: 103.5 [27-211], ATD: 73 [22-260], = 0.22). HRQoL significantly improved over time ( < 0.001) but was not affected by treatment type ( = 0.20) or thyroid status ( = 0.40). Despite improvement, HRQoL remained lower than in non-hyperthyroid controls (hyperthyroid: 42.5 [3-161.5], non-hyperthyroid: 27 [0-249], = 0.007). This study highlights the overall positive impact of treatment on HRQoL, but due to the lack of randomisation and heterogeneity of subjects and treatment, conclusion have to be considered preliminary.
先前的一项横断面研究发现，甲状腺功能亢进的猫的健康相关生活质量（HRQoL）受损，但治疗的纵向影响——尤其是放射性碘（RAIT）和抗甲状腺药物（ATD）治疗方法之间的差异——仍不清楚。本研究旨在评估最近诊断（<6个月）的甲状腺功能亢进猫在接受RAIT或ATD治疗后的HRQoL变化。在基线以及1、3和6个月后，使用经过验证的甲状腺功能亢进症QoL-猫问卷评估HRQoL，并同时评估甲状腺状态（正常/减退/亢进）。混合效应模型分析了治疗类型、时间点和甲状腺状态对log(HRQoL)的影响。使用曼-惠特尼U检验检查了基线时各组之间的HRQoL差异，以及与先前研究中第6个月的非甲状腺功能亢进对照组（n = 322）的比较。数据以中位数（范围）表示，显著性设定为<0.05。纳入了38只客户拥有的甲状腺功能亢进猫（15只接受ATD治疗，23只接受RAIT治疗）。各组在基线时的HRQoL评分没有差异（RAIT组：103.5 [27 - 211]，ATD组：73 [22 - 260]，P = 0.22）。HRQoL随时间显著改善（P < 0.001），但不受治疗类型（P = 0.20）或甲状腺状态（P = 0.40）的影响。尽管有所改善，但HRQoL仍低于非甲状腺功能亢进对照组（甲状腺功能亢进组：42.5 [3 - 161.5]，非甲状腺功能亢进组：27 [0 - 249]，P = 0.007）。本研究强调了治疗对HRQoL的总体积极影响，但由于缺乏随机化以及受试者和治疗的异质性，结论必须被视为初步的。
